MRD-directed Therapy for Low-risk and Intermediate-risk AML.

Clinical trial NCT02870777 · COMPLETED

Trial details

NCT number: NCT02870777
Sponsor: Nanfang Hospital, Southern Medical University
Status: COMPLETED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Minimal Residual Disease

Start date: 2016-08-01
Primary completion: 2019-08-31
Enrollment: 743

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.